Pacira BioSciences, Inc.
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | After market close | $192.40M | $0.12 | $0.73 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | $177.40M | $0.07 | $0.60 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $196.90M | $0.04 | $0.57 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $179.50M | $0.12 | $0.70 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $181.10M | $-0.11 | $0.74 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $168.90M | $0.10 | $0.62 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $187.30M | $0.34 | $0.91 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $168.60M | $-3.11 | $0.79 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Gross marginGAAP | 2026 | 76% to 78% | Maintained |
| Non-GAAP gross marginnon-GAAP | full-year 2026 | 77% to 79% | Maintained |
| Stock-based compensation | full-year 2026 | $54.00M to $59.00M | Lowered |
| Research and development expenseGAAP | 2026 | $115.00M to $128.00M | Lowered |
| Selling, general and administrative expenseGAAP | 2026 | $349.00M to $376.00M | Raised |
| Non-GAAP R&D expensenon-GAAP | full-year 2026 | $105.00M to $115.00M | Lowered |
| Non-GAAP SG&A expensenon-GAAP | full-year 2026 | $310.00M to $330.00M | Raised |
| EXPAREL net product sales | full-year 2026 | $600.00M to $620.00M | Lowered |
| Total revenue | full-year 2026 | $735.00M to $760.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Pacira BioSciences filed with the SEC
Viatris Agrees to Acquire Pacira
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Announces Agreement to Divest its iovera ° Business to Zimmer Biomet
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Pacira BioSciences Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Third Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees:
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira Announces Updates to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Other events · EX-99.1 to Form 8-K
Pacira BioSciences Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences, Inc. Announces Pricing of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pacira BioSciences, Inc. Announces Proposed Offering
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Pacira BioSciences Reports First Quarter 2024 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
Results of operations · EX-99.1 to Form 8-K
Pacira Appoints Frank D. Lee as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Announces Leadership Succession Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
Pacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
Results of operations · EX-99.1 to Form 8-K